A large number of single nucleotide variants (SNVs) in the human genome are known to be responsible for inherited disease. An even larger number of SNVs, particularly those located in introns, have yet to be investigated for their pathogenic potential. Using known pathogenic and neutral intronic SNVs (iSNVs), we developed the regSNPs-intron algorithm based on a random forest classifier that integrates RNA splicing, protein structure and evolutionary conservation features. regSNPs-intron showed high accuracy in computing disease-causing probabilities of iSNVs. Using a high-throughput functional reporter assay called ASSET-seq (ASsay for Splicing using ExonTrap and sequencing), we validated regSNPs-intron predictions by measuring the impact of iSNVs on splicing outcome. Together, regSNPs-intron and ASSET-seq enable effective prioritization of iSNVs for disease pathogenesis. regSNPs-intron is available at https://regsnps-intron.ccbb.iupui.edu.
Introduction
Prior to the advent of genome-wide association studies (GWAS), exploration of the relationship of genetic variants to human disease largely focused on non-synonymous single-nucleotide variants (SNVs) located in protein-coding regions. However, with the rise of next-generation sequencing, it is now clear that approximately one hundred times more variants are found in introns as compared to exons [1] . Importantly, intronic SNVs (iSNVs) can contribute to disease pathology by dysregulation of mRNA splicing [2] [3] [4] [5] .
For instance, over 3,000 disease-causing iSNVs in the Human Gene Mutation Database (HGMD) have been documented to impact splicing [6] . Most of the pathogenic variants locate close to the junction boundaries.
Intronic SNVs can impact alternative splicing by interfering with splice site recognition.
For example, an intronic mutation near the 5'-splice site of exon 20 in the IKBKAP gene causes skipping of exon 20, resulting in malfunction of IKBKAP in 99.5% of familial dysautonomia (FD) cases [5, 7, 8] . Likewise, the intron 4 splice-donor site variant in the adenomatous polyposis coli (APC) gene causes skipping of exon 4, which can lead to colon cancer [9, 10] . Additionally, iSNVs may alter the binding affinities of RNA-binding proteins (RBP) to cis-regulatory elements [2, 11, 12] . For example, a G to A substitution within an intronic-splicing enhancer downstream of exon 3 in the growth hormone (GH1) gene can cause familial isolated GH deficiency type II (IGHD II) by suppressing the binding of splicing factors [13] [14] [15] . In addition, a recent support suggests that missplicing of the GALNS gene resulting from deep intronic mutations as a cause of Morquio a disease [16] . While iSNVs are densely distributed in the genome, only a limited proportion have been investigated for associations with altered biological functions [2] .
Owing to the large number of intronic variants detected in next-generation sequencing and their complex RNA-splicing regulatory mechanisms, efficient bioinformatics algorithms are required to predict the potential impact of iSNVs and prioritize them for functional studies. One algorithm, SPANR (Splicing-based Analysis of Variants), was designed to evaluate how individual SNVs impact splicing regulation by predicting the maximum change (delta) in the percentage of inclusion (dPSI) of nearby exons induced by the SNVs. It extracts 1393 genomic features around the SNVs and predicts potential splicing outcomes by training a neural network with RNA-seq data from 16 human tissues [17] . However, SPANR was not designed to assess whether iSNVs result in deleterious phenotypes since it does not evaluate the impact of the resultant splicing change on protein function. Another widely used tool, CADD (Combined Annotation Dependent Depletion), predicts pathogenic variants with support vector machine (SVM) by combining annotations from multiple sources including: conservation scores, such as PhyloP; regulatory information, such as transcription factor binding; and protein-level predictions, such as SIFT and PolyPhen [18] . However, the annotations employed by CADD do not include RNA splicing data and provide limited information on protein function, as SIFT and PolyPhen only predict the consequences of SNVs based on amino acid substitutions. To this end, our earlier studies on small insertions/deletions (INDELs) [19, 20] , alternatively spliced exons [21] , and synonymous SNVs [22] [23] , have indicated that simply substituting a stretch of amino acid residues does not necessarily imply altered protein function. Others have also reported that nucleotide substitutions can be bystander events, i.e. non-consequential to the phenotype [24] . Therefore, in order to consider the molecular implications of functional iSNVs, it is critical to integrate features that more accurately predict the effects of alternativesplicing events on protein structure and function.
In this study, we considered the impact of iSNVs on splicing regulation together with the variant-induced impact of alternatively-spliced exons on protein-structure features. We extracted pathogenic iSNVs from the HGMD and randomly selected neutral iSNVs from the 1000 Genomes Project [6, 25] . Using these data, we developed an algorithm based on random forest classifier to compute the disease-causing probabilities of iSNVs [26] , which we have termed regSNPs-intron. This algorithm was also tested on an independent dataset selected from the ClinVar database [27] . In addition, we designed a high-throughput functional reporter assay, ASSET-seq (ASsay for Splicing using ExonTrap and sequencing), to experimentally validate the effects of the predicted iSNVs on splicing regulation. regSNPs-intron and ASSET-seq as presented here can be used in tandem to prioritize and screen potential pathogenic iSNVs to better understand their roles in complex disease.
Results

Datasets
To compute the pathogenic probabilities of iSNVs, we constructed a training set by combining the manually-curated pathogenic iSNVs in the Human Gene Mutation Database (HGMD) and neutral iSNVs from the 1000 Genomes Project (Figure 1 and Figure S1 ). Neutral iSNVs documented in the 1000 Genomes dataset were derived from genome-sequencing data from 2,500 individuals lacking obvious clinical phenotypes [1] .
In order to minimize the false negatives in our training set, we only selected those iSNVs with minor allele frequency (MAF) greater than 10%. This selection resulted in 2,438 pathogenic and 2,104,613 neutral iSNVs.
Since the proximity of an iSNV to the splice-junction site (ss) can impact the splicing outcome via different molecular mechanisms, we further divided the selected iSNVs into those proximal and distal to the splice-junction sites. For example, variants proximal to the splice-junction sites (on-ss) may directly interfere with spliceosome formation, while iSNVs distal from the junction sites (off-ss) may affect the binding of regulatory RNAbinding proteins (RBPs). Splice-junction sites were defined as the upstream 13-bp for 3′-acceptor sites and downstream 7-bp for 5′-donor sites [28] . In total, there were 1,865 on-ss and 573 off-ss pathogenic iSNVs and 3,386 on-ss and 2,104,613 off-ss neutral iSNVs. Our data show that pathogenic variants were found more frequently in regions proximal to splice-junction sites compared to neutral variants ( Figure S2 ). To avoid potential bias introduced by the variable distances of the proximal iSNVs from junction sites, we randomly selected 852 off-ss neutral iSNVs from the 1000 Genomes dataset by matching the distance distribution of the pathogenic HGMD variants. This ensured more balanced datasets with similar distance distributions between the pathogenic and neutral variants.
For each of the pathogenic and neutral on-ss and off-ss datasets, we randomly selected two-thirds of the data for use as the training set to build a random forest classifier ( Figure S1 ). The remaining one-third of the data were used as the test set. To further test the model performance, we also extracted pathogenic and neutral iSNVs from the ClinVar database as an independent test set [27] , which included 121 on-ss and 51 offss pathogenic iSNVs and 167 on-ss and 883 off-ss neutral iSNVs (see Methods section for details).
In order to select features that optimally discriminate pathogenic and neutral iSNVs, we classified all features into three categories: (i) splicing features, characterizing how individual iSNVs affect splicing regulation; (ii) structural features, evaluating how the iSNV-induced inclusion/exclusion of alternatively-spliced exons affect protein functions;
and (iii) evolutionary-conservation features, nucleotide base-wise conservation scores of 99 vertebrate genomes ( Figure 1 ). Most of the features showed significant power in separating the pathogenic and neutral iSNVs, based on the Wilcoxon rank-sum test ( Figure 2 and Table S1 ).
Disease-causing iSNVs affect alternative splicing.
To evaluate the impact of an iSNV on splicing regulation, we considered two measures:
(i) the splice-junction scores associated with proximal exons in both 5' and 3' directions, as well as the deviation of the junction score of the variant from the reference allele; and (ii) the iSNV-induced difference in RBP binding affinity. The splice-junction score was computed by position weighted matrices (PWMs) measuring sequence features around the canonical junction sites (see Methods section for details) [28] . Higher scores are more likely to include the corresponding exons in the resulting mRNA. Our results showed that pathogenic iSNVs were more frequently associated with lower splicejunction scores. The median junction score of pathogenic on-ss iSNVs was 7.37 and 7.11 for donor and acceptor sites, respectively, compared to 7.95 and 7.84 for neutral iSNVs (adjusted p-value 0.017 and 1.35*10 -7 , respectively) (Table S1 ). For pathogenic off-ss iSNVs, the median junction scores were 7.63 and 7.95 for donor and acceptor sites, compared to 8.13 and 8.54 for neutral off-ss iSNVs (adjusted p-value 0.018 and 9.0*10 -4 , respectively) (Table S1 ). In addition to the junction scores, the deviation of the junction score resulting from each on-ss iSNV was calculated. The median deviation values for pathogenic iSNVs were -2.96 and -2.23 for donor and acceptor sites, respectively. The magnitude of these deviations was significantly larger than those of neutral iSNVs, which were 0.034 and -0.059 for donor and acceptor sites, respectively ( Figure S3 ). The adjusted Wilcoxon rank-sum test p-values for donor and acceptor sites were 1.63*10 -211 and 1.28*10 -143 , respectively (Table S1 and Figure S3 ). These results indicate that pathogenic iSNVs are strongly associated with exon skipping.
To evaluate the impact of an iSNV on RBP binding, we computed both the magnitude and probability of binding score changes caused by the iSNVs for 201 RBPs with known PWMs. We found that pathogenic and neutral iSNVs showed significant differences in the binding of many RBPs. Generally, the pathogenic on-ss and off-ss iSNVs induced large binding score changes in 191 and 176 RBPs, respectively, compared to the respective neutral iSNVs. Specifically, 137 RBPs showed significant differences in iSNV-induced binding scores between on-ss pathogenic and neutral variants, whereas 43 RBPs showed significant differences between off-ss pathogenic and neutral variants (adjusted Wilcoxon rank-sum test p-value < 0.05; Table S1 and Figure S4 ). Taken together, these findings provide strong evidence for pathogenic iSNVs affecting splicing regulation resulting in altered mRNA structures.
Disease-causing iSNVs are associated with exons encoding functionally important protein domains.
To evaluate the impact of iSNVs on protein function, we examined the structural features corresponding to potential alternatively spliced exons. We hypothesized that pathogenic iSNVs disrupt the splicing of exons that encode key protein structural domains. We captured the protein structural features for the closest neighboring exons of the iSNVs including intrinsic disorder score, secondary structure (e.g. alpha helix, beta sheet or random coil), and solvent accessible surface areas (ASA) (Table S1) [29, 30] . We also calculated the overlap percentage of the target exon with known protein domains, as well as the number of known post-translational modification sites within the exon-encoded protein domain (Table S1) [31, 32] .
We found that exons in proximity to pathogenic iSNVs were more likely to encode protein domains that had lower average disorder scores and contained longer structured regions, compared to exons proximal to neutral iSNVs (adjusted Wilcoxon rank-sum test p-value 2.03×10 -11 and 0.0497 for on-ss and off-ss iSNVs, respectively) (Table S1 and Figure S5 ). This result indicates that pathogenic iSNVs have a higher probability of being proximal to exons encoding structured regions. In addition, proximal exons to pathogenic iSNVs had significantly smaller average ASA scores (adjusted pvalue 2.90×10 -13 and 0.0103 for on-ss and off-ss iSNVs, respectively), which indicates that they are more likely to encode regions in the protein core as opposed to regions on the protein surface. Moreover, the closest exons to pathogenic iSNVs encoded a significantly higher percentage of residues that overlapped with known protein domains (adjusted p-value 1.91×10 -16 and 1.98×10 -5 for on-ss and off-ss iSNVs, respectively).
Taken together, these results show that exons proximal to pathogenic iSNVs are more likely to encode functionally important protein regions. On the other hand, our analysis also suggests that protein structural features provide valuable information for prioritizing disease-causing iSNVs.
Disease-causing iSNVs localize to conserved regions.
Previous studies showed that evolutionary conservation is an important feature in assessing the disease-causing potential of SNVs [33, 34] . To determine whether an iSNV was evolutionarily conserved, we calculated the PhyloP 100-way conservation score of the iSNV locus, and the mean conservation score of a region flanking either side of the candidate iSNV by a length of 3 bp as well as 7 bp. Our results showed that pathogenic iSNVs had significantly higher PhyloP conservation scores than neutral iSNVs ( Figure S6 ). The median conservation score for on-ss pathogenic iSNV loci was 3.08, which was significantly higher than the score of -0.03 for neutral on-ss iSNVs (adjusted Wilcoxon rank-sum test p-value <1×10 -300 ). Likewise, the median score for offss pathogenic iSNV loci was 0.31, compared to -0.28 for neutral off-ss iSNVs (adjusted p-value 3.21×10 -38 ). The large positive PhyloP scores for the pathogenic iSNV loci suggested that they evolved much more slowly than the neutral loci. Conservation scores for the 3-bp and 7-bp flanking regions were consistent with the iSNV loci scores.
For the 3-bp flanking regions around the on-ss and off-ss pathogenic iSNVs, the respective medians of their mean conservation scores were 2.86 and 0.23, compared to 0.58 and -0.07 for the neutral iSNVs (adjusted p-values 1×10 -300 and 5.47×10 -23 , respectively). Similar results were also found for the 7-bp flanking regions. These findings indicate that iSNVs at more conserved loci are more likely to be pathogenic.
regSNPs-intron model building, performance, and evaluation.
Based on the splicing, protein structure, and evolutionary conservation features described above (Table S1) To further evaluate predictive powers of the features related to splicing, structure and conservation, we built separate models based on features from each of these three categories. For on-ss iSNVs, the AUROCs for splicing, structure and conservation features were 0.92, 0.72 and 0.92 respectively; for off-ss iSNVs, the AUROCs were 0.75, 0.63 and 0.68 respectively ( Figure S7 ). These results demonstrate that each category of features provides important information in model prediction, and thus, the combination of all three categories yields the highest performance. 
Evaluation of model performance using an independent test set.
We further evaluated regSNPs-intron performance with an independent dataset from ClinVar (described above). All the ClinVar iSNVs that were also observed in HGMD or 1000 Genomes datasets were excluded from the training set to avoid overfitting. Consistent with the results described above, the regSNPs-intron model showed better performance compared to SPANR. The regSNPs-intron AUROCs were 0.96 and 0.95 for on-ss and off-ss iSNVs, respectively, whereas the SPANR AUROCs were 0.89 and 0.72 for on-ss and off-ss iSNVs, respectively ( Figure 3C and 3G). We did not include CADD in this comparison since the ClinVar data were used in its original model training [18] . These results suggest that regSNPs-intron exhibits stable performance and higher prediction accuracy compared to SPANR over different datasets.
Allele frequency was inversely correlated with disease-causing probability.
Generally, allele frequency in the population should reflect the importance of the biological function of a variant [35] [36] [37] [38] [39] . Therefore, we examined the relationship between allele frequency and the predicted disease-causing probability of iSNVs obtained from the Exome Aggregation Consortium (ExAC) and the Genotype-Tissue Expression Project (GTEx), respectively. The iSNVs were divided into 20 bins based on their allele frequencies. For each bin, the average disease-causing probability of all the iSNVs within the bin were calculated. A strong negative correlation was observed between allele frequency and disease-causing probability for both on-ss iSNVs (ExAC R 2 = -0.32, GTEx R 2 = -0.47) and off-ss iSNVs (ExAC R 2 = -0.77, GTEx R 2 = -0.90) ( Figure 3D and 3H ). This result is consistent with the findings of others that variants with higher disease-causing probability are less likely to occur in the general population [20] .
Disease-causing iSNVs occur near exons associated with high disease-causing probability.
We further evaluated the regSNPs-intron predictions by investigating the functional importance of exons that are proximal to iSNVs. We hypothesized that functionally important exons tolerate fewer nearby iSNVs compared to exons not associated with disease. To test this hypothesis, we extracted 75,119 exons that had at least one iSNV within ±300 bp of exon-intron boundaries based on ExAC data. One iSNV was randomly selected per exon and the disease-causing probabilities were predicted using regSNPsintron. We observed a significant negative correlation between the predicted average disease-causing probability and the number of iSNVs near exons (R 2 = -0.85, p-value = 6.26×10 -11 ) ( Figure 4 ). The same analysis was also performed on 160,230 exons which had at least one iSNV within ±300 bp of exon-intron boundaries based on GTEx whole genome sequencing data. A similar negative correlation was observed (R 2 = -0.61, pvalue = 0.07). This result indicates that pathogenic iSNVs tend to occur near functionally important exons.
Prioritizing functional intronic variants associated with drug-induced cytotoxicity.
We applied regSNPs-intron to prioritize intronic variants that are associated with cellular sensitivity to clofarabine-induced cytotoxicity. We have previously performed genomewide association studies (GWAS) for the clofarabine-response phenotype (AUC for drug-induced cytotoxicity curves) using 90 International HapMap lymphoblastoid cell lines (LCLs) of the CEU population [40] . SNVs moderately associated with clofarabine cytotoxicity (p-value ≤ 0.05) were selected as seed markers. All 17,962 iSNVs that were in linkage-disequilibrium (LD) with the seed markers and were located within 300 bp upor down-stream of a splice junction were used in the predictions. Among these candidate variants, 622 and 84 iSNVs were predicted to be Damaging (FPR ≤ 0.05) and
Possibly Damaging (0.05 < FPR ≤ 0.1), respectively (706 in total).
Experimental validation using ASSET-seq assay.
To experimentally validate the effects of the prioritized iSNVs on the splicing outcome, we designed a high-throughput functional reporter assay called ASSET-seq, that entails inserting an oligo containing an iSNV into a modified Exontrap plasmid ( Figure 5A ) [41] .
The impact on splicing outcome of the tested iSNV was measured as the difference between the respective ratios of the sequencing reads supporting spliced and aberrant (including unspliced) transcripts for the reference and alternative alleles. The difference in the ratios for the two types of splicing outcomes between the reference and alternative alleles was analyzed by a mixed-effect model.
We used ASSET-seq to test the effects of 82 iSNVs on splicing outcomes in three different human cell lines: HeLa, HEK293, and HepG2. These variants were chosen from the 706 prioritized regSNPs-intron candidates (FPR ≤ 0.1) as being located in the intron on the 3′-side of the test exon and within 60 nt from the exon-intron junction, based on assay design requirements (see details in Methods). Upon removing 19 failed assays (e.g. transfection or PCR failure), the percentages of the 63 remaining iSNVs showing significant splicing impact, i.e. validation rates, for the three cell lines were:
HeLa 64.4%, HEK293 96.6%, and HepG2 64.7% (FDR ≤ 0.1 in accord with the FPR; Figure 5B and Supplemental Table S2 ). One specific example, rs6538694 in the HAL gene, is shown in Figure 5C . Across all three cell lines (5 replicates each), a significantly higher percentage of spliced gene products was observed for the reference allele compared to the alternative allele (p-values ≤ 4.6×10 -5 ). For the reference allele, the average percentage of sequencing reads supporting the spliced gene product was 88.4%, while this percentage dropped to 57.1% for the alternative allele. Moreover, we observed high consistency for the impacts of individual iSNVs on splicing outcomes across the multiple cell lines ( Figure 5D ).
Discussion
The major conclusions of the current study are that RNA-splicing, protein-structural and evolutionary-conservation features all contribute to iSNV pathogenicity characterization.
By integrating these three categories of feature, the regSNPs-intron algorithm efficiently evaluates the disease-causing probabilities of iSNVs in silico. These conclusions are based on the following evidence. First, we demonstrated that disease-causing iSNVs affect alternative splicing, localize to conserved genomic regions, and are associated with functional domain-encoding exons. Next, we provided strong evidence that regSNPs-intron has superior accuracy in computing the disease-causing probabilities for iSNVs compared to SPANR and CADD, based on 1000 Genomes and HGMD data, as well as with independent ClinVar data. Furthermore, we applied regSNPs-intron to a GWAS dataset of drug-cytotoxicity and experimentally validated the prioritized iSNVs via ASSET-seq. Taken together, this evidence strongly supports the overall concept that the regSNPs-intron algorithm, combined with the ASSET-seq assay, will facilitate studies on the regulatory functions of iSNVs and their potential roles in disease and/or drug response.
Although information on variant-induced disruption of splicing and variant conservation
has been used to evaluate the impact of synonymous variants [17] , our previous studies have shown that protein structural features greatly improve the prioritization of pathogenic micro-insertions/deletions as well as alternative-splicing events [20, 21] .
Prompted by our earlier findings, we proposed that protein-structural features might also be informative in predicting the pathogenic effects of iSNVs. This idea was also supported by the finding that pathogenic iSNVs tend to be localized in the vicinity of exons encoding functionally important protein domains. Following the common practice of integrating multi-level features, as in algorithms such as SPANR and CADD, regSNPs-intron constitutes the first bioinformatics tool specifically designed to predict pathogenic iSNVs.
Intronic variants are typically identified by whole-genome sequencing (WGS), but they can also be captured by whole-exome sequencing (WES), particularly those iSNVs close to splice junctions that may be functionally important. To estimate the number of these intronic variants, we surveyed all the genetic variants documented in the ExAC database, which includes high-quality exome sequencing data from 60,706 unrelated individuals from a variety of large-scale sequencing projects such as the NHLBI exome sequencing project (ESP) and the 1000 Genomes project [42] . Among 7, 908, 659 documented SNVs in the ExAC database, these iSNVs account for 52.2% (4,126,724); therefore, identifying which of these iSNVs is important for disease pathogenesis is crucial for human genetics research. Thus, the regSNPs-intron algorithm should serve as a valuable tool for the prioritization of intronic variants, detected through WES and WGS experiments, for functional analysis.
In order to experimentally validate the impact of predicted pathogenic iSNVs on splicing regulation, we developed an innovative experimental approach, ASSET-seq. Although this assay was able to verify splicing alterations, there were a few limitations. Not surprisingly, results were influenced by technical noise from multiple sources, such as cell transfection, sequencing or PCR, that served to confound the analysis. Since these effects could not be entirely prevented, we assumed heterogeneity among the sample replicates, and applied the generalized mixed-effect model to characterize the significance of change in splicing outcomes (i.e. correlation between allele types and spliced products). Interestingly, most of the regSNPs-intron predicted candidates displayed significant impact on splicing regulation in multiple cell lines. Specifically,
HEK293 cells exhibited an excellent validation rate and low noise; whereas, HeLa and
HepG2 cells had lower validation rates, possibly due to larger data variabilities (high noise). Thus, our validation results confirm the effectiveness of regSNPs-intron in prioritizing iSNVs. In addition, although we tested a relatively small number of variants in this study, ASSET-seq can be extended to allow it to operate on a much larger scale.
In conclusion, we found that integrating RNA-splicing, protein-structural and evolutionary-conservation features lead to superior characterization of disease-causing iSNVs. Using regSNPs-intron and ASSET-seq in tandem enables the effective prioritization of disease-causing iSNVs. This is expected to accelerate the identification of pathogenic iSNVs, a core task of genome-wide sequencing studies.
Methods
Splicing features.
A junction score for the closest exon boundary of each iSNV was calculated based on the position weight matrices (PWMs) derived from canonical splice sites [28] . The junction score was measured by summing the information contents of positions from -3 to +7 for donor sites, and positions from -13 to +1 for acceptor sites. In addition, for onss iSNVs, the change in junction score caused by allele substitution was also computed and used as a feature.
The impact of iSNVs on RBP binding affinity was measured based on the PWMs obtained from the RBPDB and cisBP-RNA databases [43, 44] . A total of 201 PWMs were collected and the magnitude and posterior probabilities of RBP binding changes were measured using methods described previously [19] . The matching score was calculated as: ).
The mean and variance of matching score distributions for binding and non-binding events were estimated as:
is the approximation of the true frequency of base The magnitude of how an iSNV affects RBP binding was defined as the log-likelihood ratio between the alternative and reference alleles: A Bayesian-based posterior probability of the RBP binding change was calculated as:
Protein structural features.
For each iSNV, protein-structural features of its closest exons were evaluated. The protein-disorder score, secondary structure and solvent accessible surface area (ASA)
were precomputed for all known protein-coding genes using SPINE-D and SPINE-X [29, 30] . The known protein domains were extracted from the Pfam database [31] .
Percentages of the closest exon regions that overlap with Pfam domains were measured. The post-translational modification sites (PTMs) were extracted from the dbPTM 3.0 database [32] . The number of PTM sites per 100 amino acids encoded by the closest exons were also calculated.
Evolutionary-conservation features.
Base-wise conservation scores (PhyloP) of 99 vertebrate genomes were downloaded from UCSC Genome Browser [45] . The scores on the iSNVs loci, as well as the average scores of the 3-bp and 7-bp window regions around the iSNVs, were extracted and used in machine learning.
Machine learning model.
Separate random forest classifiers were built for on-ss and off-ss iSNVs respectively. A grid search strategy with 3-fold cross-validation was used on the training set to fine-tune the hyperparameters, such as the number of trees and the maximum tree depth.
ClinVar database iSNVs.
ClinVar (version 2016/05/31) was downloaded from NCBI (ftp://ftp.ncbi.nlm.nih.gov/pub/clinvar/). We extracted the SNVs located in intronic regions. To ensure the quality of data, we only included the iSNVs that were confirmed by at least two submitters, with the exception of pathogenic off-ss iSNVs where we only required a single submitter due to the limited number of such iSNVs.
GTEx and ExAC database iSNVs.
SNVs from whole-genome sequencing data in GTEx release v6 were downloaded in the VCF format. We focused on the iSNVs within 300 bp of exon-intron boundaries. In total, there were 17,194 on-ss iSNVs and 630,557 off-ss iSNVs. Similarly, we also downloaded the variant loci from whole-exome sequencing data in ExAC r0.3.1.
Corresponding allele frequencies were calculated for correlation analysis with predicted disease-causing probabilities.
ASSET-seq plasmid construction.
The modified Exontrap plasmid is shown in Figure 4A and the sequence is provided in Supplemental Text S1. The test oligos consisted of 11 bp of the upstream exon and 60 bp of the adjacent intron containing the iSNV to be tested. Additional 22-bp exonic and 19-bp intronic sequences homologous to the vector were also included for the seamless insertion of the oligos into the plasmid body. Further, a single nucleotide barcode was introduced to indicate whether the transcript came from the wild-type or variant construct. The 113-bp oligos containing different test iSNVs were synthesized in parallel as a pool using OligoMix (LC Sciences, Houston TX). In the present study, the ASSETseq assays contained 82 pairs of reference and variant test sequences. The synthesized oligos were then cleaved from the chip, and amplified via high fidelity PCR
with primers paired to the exon and intron homology sequences (Supplemental Text S1).
The pooled oligos were directionally inserted into the Exontrap plasmid using the NEBuilder HiFi DNA Assembly Reaction (New England Biolabs, Ipswich MA). The assembled plasmids were transformed into bacteria and plated on LB agar plates containing ampicillin. The resulting colonies were scraped and grown in LB + ampicillin medium. Plasmid DNA was isolated using HiSpeed Plasmid Maxi kit (Qiagen, Germantown MD).
Transfection of cell culture.
The plasmid library was used to transfect three human cell lines: HeLa, HEK293, and
HepG2. The cells were seeded at a density of 0.9 x 10 5 in 24-well plates. Each plate 
RNA isolation and cDNA synthesis.
Transfected cells were were lysed in situ 48 hours after transfection and total RNA was isolated using miRNeasy mini kit with the optional DNase digestion step (Qiagen, Germantown MD) following the manufacture's protocol. Using 285-400 ng RNA, cDNA was synthesized with QuantiTect Reverse Transcription kit (Qiagen, Germantown MD)
following the manufacturer's protocol.
Molecular barcoding.
To identify the source cell line and replicate of the RNA transcripts, cDNA generated from the plasmid library in the transfected cells was PCR amplified using barcoded primers. A unique 6-nt sequence was added to the 5'-end of the forward and reverse primer for identification (Supplemental Text S1). In separate PCR reactions, 2 µL cDNA were amplified in a 50 µL volume containing 2X Invitrogen Platinum SuperFi PCR Next-generation sequencing.
The pooled PCR products were sequenced using the NextSeq 500 platform (Illumina, Inc., San Diego, CA). The sequencing library was created by end-polishing the barcoded PCR products, followed by adapter ligation and amplification. The resulting library was quantified and its quality was assessed with the Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA). Approximately 90 million usable reads were generated.
Raw reads were generated as fastq files for bioinformatics analysis.
Bioinformatics analysis for sequencing data.
Illumina sequencing adapters were first removed from the raw reads in the fastq files using the tool cutadapt (v1.9.1) [46] . Then the reads were demultiplexed into the 20 sequence groups according to the barcodes. Sequencing reads were aligned to the transcripts using STAR (Spliced Transcripts Alignment to a Reference, v2.5.3a) [47] .
The reference sequence for the alignment was built based on the plasmid (Supplemental Text S1), and read counts for the spliced and aberrant (including unspliced) transcripts were documented.
Statistical analysis.
Assuming the heterogeneity among the sample replicates, we applied the generalized linear mixed-effect model to characterize the difference of splicing patterns between reference and alternative alleles in each of the three experimental cell lines. Specifically, to determine whether there was a significant change in splicing outcome (described by counts of sequencing reads supporting the spliced and aberrant transcripts) between the two alleles, we defined x allele and x splice as two binary variables (i.e. 0 or 1) in the following regression equation:
Here Y is the sequencing read count, which follows negative binominal distribution, and ε is the random effect among the multiple replicates. The impact induced by an iSNV on splicing was considered significant if the coefficient β 3 was non-zero and the associated p-value was less than 0.1. Supplemental Table S1 for details. The x-axis is the median score difference, which was defined as: median score of pathogenic iSNVsmedian score of neutral iSNVs. Feature scores were calculated as described in Methods. The yaxis is -log10 of Wilcoxon rank-sum test p-value (Benjamini-Hochberg, i.e. FDR adjusted). HeLa versus HepG2 = 0.959 (red, p-value = 6.66×10 -40 ), HEK versus HepG2 = 0.894 (green, pvalue = 6.65×10 -29 ). Solid lines in dark blue, red, and green represent regressions. Table S1 . Complete list of model features and their individual predictive powers. Table S2 . Additional data for ASSET-seq experiment result.
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